Thrombin Mutant W215A/E217A Acts as a Platelet GPIb Antagonist

Michelle A. Berny‐Lang, Tara C. White, Erik I. Tucker, Leslie A. Bush-Pelc, Enrico Di, András Gruber, Owen J. T. McCarty

Arteriosclerosis Thrombosis and Vascular Biology · 2007 · 45 citations · 24 references

DOIFull text

Open access

Concepts

Abstract

OBJECTIVE: Thrombin containing the mutations Trp215Ala and Glu217Ala (WE) selectively activates protein C and has potent antithrombotic effects in primates. The aim of this study was to delineate the molecular mechanism of direct WE-platelet interactions under static and shear conditions. METHODS AND RESULTS: Purified platelets under static conditions bound and spread on immobilized wild-type but not WE thrombin. In PPACK-anticoagulated blood under shear flow conditions, platelets tethered and rolled on both wild-type and WE thrombin, and these interactions were abrogated by the presence of a glycoprotein Ib (GPIb)-blocking antibody. Platelet deposition on collagen was blocked in the presence of WE, but not wild-type thrombin or prothrombin. WE also abrogated platelet tethering and rolling on immobilized von Willebrand factor in whole blood under shear flow. CONCLUSIONS: These observations demonstrate that the thrombin mutant WE, while not activating platelets, retains the ability to interact with platelets through GPIb, and inhibits GPIb-dependent binding to von Willebrand factor-collagen under shear.

References

24